Dulaglutide
INTERCEPT
Company n/r · Phase n/r · Completed · Enrollment 60000
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Initiation of dulaglutide, semaglutide or tirzepatide | n/r | n/r | n/r | n/r |
| Initiation of sitagliptin | n/r | n/r | n/r | n/r |
Not shown
- Initiation of dulaglutide, semaglutide or tirzepatide: endpoint not reported
- Initiation of sitagliptin: endpoint not reported